JP2020533971A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533971A5 JP2020533971A5 JP2020511477A JP2020511477A JP2020533971A5 JP 2020533971 A5 JP2020533971 A5 JP 2020533971A5 JP 2020511477 A JP2020511477 A JP 2020511477A JP 2020511477 A JP2020511477 A JP 2020511477A JP 2020533971 A5 JP2020533971 A5 JP 2020533971A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- cells
- soluble
- protein complex
- soluble fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551218P | 2017-08-28 | 2017-08-28 | |
| US62/551,218 | 2017-08-28 | ||
| PCT/US2018/048365 WO2019046313A1 (en) | 2017-08-28 | 2018-08-28 | IL-15 BASED FUSIONS WITH IL-7 AND IL-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533971A JP2020533971A (ja) | 2020-11-26 |
| JP2020533971A5 true JP2020533971A5 (enExample) | 2021-10-07 |
Family
ID=65526059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511477A Withdrawn JP2020533971A (ja) | 2017-08-28 | 2018-08-28 | Ｉｌ−１５をベースとするｉｌ−７及びｉｌ−２１への融合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11161890B2 (enExample) |
| EP (1) | EP3676289B1 (enExample) |
| JP (1) | JP2020533971A (enExample) |
| KR (1) | KR20200090742A (enExample) |
| CN (1) | CN111655716B (enExample) |
| AU (1) | AU2018323455B2 (enExample) |
| CA (1) | CA3074635A1 (enExample) |
| WO (1) | WO2019046313A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2160401T3 (da) * | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| US12006512B2 (en) * | 2017-01-20 | 2024-06-11 | Kyoto University | Method for producing CD8alpha+beta+ cytotoxic t cells |
| EP3592778A4 (en) | 2017-03-06 | 2021-01-13 | Altor BioScience Corporation | IL-15-BASED FUSIONS TO IL-12 AND IL-18 |
| KR20200090742A (ko) | 2017-08-28 | 2020-07-29 | 알토 바이오사이언스 엘엘씨 | Il-7 및 il-21에의 il-15 기반 융합 |
| WO2020037120A1 (en) * | 2018-08-16 | 2020-02-20 | Nantbio, Inc. | Il7-il15 txm compositions and methods |
| JP7397874B2 (ja) | 2018-08-30 | 2023-12-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| CN120535649A (zh) | 2018-08-30 | 2025-08-26 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| AU2019328575B2 (en) | 2018-08-30 | 2024-07-11 | Immunitybio, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| GB201818816D0 (en) * | 2018-11-19 | 2019-01-02 | Synpromics Ltd | Regulatory nucleic acid sequences |
| CN111825770B (zh) * | 2019-04-16 | 2023-06-09 | 成都医学院 | 长效白介素21-Fc融合蛋白及其用途 |
| WO2020257639A1 (en) * | 2019-06-21 | 2020-12-24 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| GB201909144D0 (en) | 2019-06-25 | 2019-08-07 | Autolus Ltd | Culture medium |
| US11453862B2 (en) | 2019-07-08 | 2022-09-27 | Immunitybio, Inc. | Mononuclear cell derived NK cells |
| CN113166726A (zh) * | 2019-07-08 | 2021-07-23 | 南克维斯特公司 | 单核细胞源性nk细胞 |
| US20210061871A1 (en) * | 2019-08-29 | 2021-03-04 | Nantbio, Inc. | Modified N-810 and Methods Therefor |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| AU2021220196A1 (en) | 2020-02-11 | 2022-08-04 | HCW Biologics, Inc. | Methods of activating regulatory T cells |
| CA3169231A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| US12187763B2 (en) | 2020-02-11 | 2025-01-07 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
| WO2021247003A1 (en) * | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| EP4157460A1 (en) * | 2020-06-01 | 2023-04-05 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| GB202008957D0 (en) | 2020-06-12 | 2020-07-29 | Autolus Ltd | Culture medium |
| US12024559B2 (en) | 2020-10-23 | 2024-07-02 | Asher Biotherapeutics, Inc. | Fusions with CD8 antigen binding molecules for modulating immune cell function |
| GB2638094B (en) | 2021-05-19 | 2026-03-04 | Asher Biotherapeutics Inc | IL-21 Polypeptides And Targeted Constructs |
| EP4351320A1 (en) | 2021-06-09 | 2024-04-17 | ImmunityBio, Inc. | Methods and systems for producing a protein of interest in a plant |
| US20250051414A1 (en) * | 2021-06-30 | 2025-02-13 | The Regents Of The University Of California | Altering cytokine specificity through binding valency |
| CN113549158B (zh) * | 2021-07-19 | 2022-10-21 | 广州百暨基因科技有限公司 | 包含突变型il15以及嵌合抗原受体的融合蛋白 |
| CN119384289A (zh) | 2022-04-13 | 2025-01-28 | 免疫生物公司 | 用于治疗神经炎症性障碍的多链嵌合多肽 |
| AU2023259161A1 (en) * | 2022-04-27 | 2024-11-28 | Asher Biotherapeutics, Inc. | Combination of cytokine fusion proteins with cd8 antigen binding molecules |
| US20260048099A1 (en) * | 2022-08-16 | 2026-02-19 | The United States Of America, As Represented By The Secretary, Deparment Of Health And Human Service | Synergistic interactions for improved cancer treatment |
| EP4683949A1 (en) * | 2023-03-23 | 2026-01-28 | Gilead Sciences, Inc. | Tnf superfamily member immunocytokine and uses thereof |
| CN117186243B (zh) * | 2023-07-26 | 2025-08-19 | 四川三优康生物技术有限公司 | 猪白细胞介素15，21和23共表达生物制剂材料及应用 |
| WO2025064822A2 (en) * | 2023-09-20 | 2025-03-27 | Factor Bioscience Inc. | Cells and methods for engineering cells with persistent transgene expression |
| CN117050178B (zh) * | 2023-10-13 | 2024-01-12 | 北京百普赛斯生物科技股份有限公司 | 特异性检测il-7的抗体及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US222A (en) | 1837-06-10 | Truss for the retention and radical cure qe hernia | ||
| US8507A (en) | 1851-11-11 | petess | ||
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| WO1994004689A1 (en) | 1992-08-14 | 1994-03-03 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant toxin with increased half-life |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5534592A (en) | 1995-09-22 | 1996-07-09 | The Goodyear Tire & Rubber Company | High performance blend for tire treads |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US8772451B2 (en) | 2003-11-10 | 2014-07-08 | Altor Bioscience Corporation | Soluble TCR molecules and methods of use |
| DK2160401T3 (da) * | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
| EP2619229B1 (en) | 2010-09-21 | 2016-04-06 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| JP2018529753A (ja) * | 2015-10-06 | 2018-10-11 | ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー | 転移性及び難治性癌及び腫瘍の処置のための方法及び組成物 |
| KR102392142B1 (ko) | 2016-10-21 | 2022-04-28 | 알토 바이오사이언스 코포레이션 | 다량체 il-15 기반 분자 |
| KR20200090742A (ko) | 2017-08-28 | 2020-07-29 | 알토 바이오사이언스 엘엘씨 | Il-7 및 il-21에의 il-15 기반 융합 |
-
2018
- 2018-08-28 KR KR1020207009046A patent/KR20200090742A/ko not_active Ceased
- 2018-08-28 WO PCT/US2018/048365 patent/WO2019046313A1/en not_active Ceased
- 2018-08-28 EP EP18851494.7A patent/EP3676289B1/en active Active
- 2018-08-28 CA CA3074635A patent/CA3074635A1/en not_active Abandoned
- 2018-08-28 CN CN201880070462.7A patent/CN111655716B/zh active Active
- 2018-08-28 JP JP2020511477A patent/JP2020533971A/ja not_active Withdrawn
- 2018-08-28 US US16/114,870 patent/US11161890B2/en active Active
- 2018-08-28 AU AU2018323455A patent/AU2018323455B2/en active Active
-
2021
- 2021-10-18 US US17/504,100 patent/US11965007B2/en active Active
-
2023
- 2023-09-21 US US18/472,053 patent/US12410224B2/en active Active
-
2024
- 2024-07-17 US US18/775,868 patent/US20240368237A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10428119B2 (en) | Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes | |
| AU2007271398B2 (en) | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses | |
| JP2023123877A (ja) | 養子細胞療法のための腫瘍浸潤リンパ球 | |
| JP2020508691A5 (enExample) | ||
| CN110198737A (zh) | 靶向psma的三特异性蛋白质及使用方法 | |
| JP2005520853A (ja) | 蛋白質ワクチン接種の有効なアジュバントとしての抗体融合蛋白質 | |
| RU2183215C2 (ru) | Конъюгат для стимулирования иммунной реакции против клетки-мишени, способ лечения злокачественных опухолей у млекопитающего | |
| JP2020536573A5 (enExample) | ||
| AU2012268013A1 (en) | Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes | |
| JP2019520309A (ja) | 炎症性免疫サイトカインおよびキメラ抗原受容体（ｃａｒ）−ｔ細胞を含む併用治療 | |
| JP2022502015A5 (enExample) | ||
| KR102578682B1 (ko) | Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells) | |
| WO2007016185A2 (en) | Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination | |
| CN119264269A (zh) | 结合cd19的嵌合抗原受体及其用途 | |
| ES2358118T3 (es) | Procedimiento para la obtención de anticuerpos humanos que neutralizan la actividad biológica de una citoquina humana. | |
| Selinsky et al. | Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo | |
| CA3198822A1 (en) | Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides | |
| WO2021092719A1 (zh) | 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白 | |
| WO2003045997A2 (en) | Fusion proteins containing tlp peptides | |
| RU2024116904A (ru) | Улучшенные антигенсвязывающие рецепторы | |
| US20090148440A1 (en) | Antibodies against interleukin-22 binding protein and its uses for the treatment of metabolic disorders | |
| JP7822652B2 (ja) | 新規なｐｄｌ１単一ドメイン抗体の開発 | |
| CN119367516A (zh) | 一种免疫调节因子组合物及其应用 | |
| KR101286065B1 (ko) | 항-Ｈｅｒ-2／ｎｅｕ 키메라 면역 수용체를 발현하는 사이토카인 유도 살해세포, 이를 포함하는 약제학적 조성물 및 이를 이용한 종양 치료 방법 | |
| JP2024527963A5 (enExample) |